Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Checkmate Pharmaceuticals, Inc. (CMPI)

10.5   0 (0%) 12-31 19:00
Open: 10.49 Pre. Close: 10.5
High: 10.5 Low: 10.49
Volume: 63,651 Market Cap: 0(M)

Technical analysis

as of: 2022-11-18 4:19:32 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 12.26     One year: 14.32
Support: Support1: 10.49    Support2: 10.48
Resistance: Resistance1: 10.5    Resistance2: 12.26
Pivot: 10.5
Moving Average: MA(5): 10.5     MA(20): 10.5
MA(100): 10.5     MA(250): 7.51
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 100     %D(3): 100
RSI: RSI(14): 88.8
52-week: High: 10.5  Low: 2
Average Vol(K): 3-Month: 64 (K)  10-Days: 64 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CMPI ] has closed Bollinger Bands are 0% narrower than normal.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.51 - 10.56 10.56 - 10.6
Low: 10.37 - 10.43 10.43 - 10.48
Close: 10.41 - 10.5 10.5 - 10.58

Company Description

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.

Headline News

Thu, 12 May 2022
Checkmate Pharmaceuticals Announces First Quarter 2022 ... - GlobeNewswire

Sun, 24 Apr 2022
U.S stock market gainers for the week - Nairametrics

Fri, 22 Apr 2022
StockWatch: Checkmate Shares Quadruple on Regeneron Buyout - Genetic Engineering & Biotechnology News

Tue, 19 Apr 2022
Regeneron To Acquire Checkmate Pharmaceuticals and Its ... - Goodwin Procter

Tue, 29 Mar 2022
Checkmate Pharmaceuticals Announces Full Year 2021 Financial ... - GlobeNewswire

Wed, 09 Feb 2022
Checkmate Pharmaceuticals Appoints Alan Bash as President and ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 22 (M)
Shares Float 7 (M)
% Held by Insiders 4.6 (%)
% Held by Institutions 77.5 (%)
Shares Short 79 (K)
Shares Short P.Month 42 (K)

Stock Financials

EPS -2.93
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.53
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -42.4
Return on Equity (ttm) -75.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -50 (M)
Levered Free Cash Flow -24 (M)

Stock Valuations

PE Ratio -3.6
PEG Ratio -0.1
Price to Book value 4.13
Price to Sales 0
Price to Cash Flow -4.63

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.